Ikko Tomisaki

Kitakyushu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors.

Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors.

Journal: Anticancer research

Published: May 26, 2026

Real-world Outcomes of First-line Platinum-based Chemotherapy in Patients Aged 80 Years or Older With Metastatic Urothelial Carcinoma.

Real-world Outcomes of First-line Platinum-based Chemotherapy in Patients Aged 80 Years or Older With Metastatic Urothelial Carcinoma.

Journal: Cancer diagnosis & prognosis

Published: May 11, 2026

Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study.

Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study.

Journal: International journal of clinical oncology

Published: May 01, 2026

Reduced Uncoupling Protein 1 Expression in Periprostatic Adipose Tissue and Its Association With Higher Prostate Cancer Grade.

Reduced Uncoupling Protein 1 Expression in Periprostatic Adipose Tissue and Its Association With Higher Prostate Cancer Grade.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: March 22, 2026

Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.

Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.

Journal: Cancer diagnosis & prognosis

Published: October 11, 2025

Immune Checkpoint Inhibitor Retreatment after Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Descriptive Study with Exploratory Evaluation of Radiotherapy.

Immune Checkpoint Inhibitor Retreatment after Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Descriptive Study with Exploratory Evaluation of Radiotherapy.

Journal: JMA journal

Published: September 22, 2025

Adjuvant Nivolumab Therapy for Upper Tract Urothelial Carcinoma: A Single-Institution Study.

Adjuvant Nivolumab Therapy for Upper Tract Urothelial Carcinoma: A Single-Institution Study.

Journal: Cureus

Published: August 11, 2025

Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.

Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.

Journal: Journal of kidney cancer and VHL

Published: June 25, 2025

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.

Journal: In vivo (Athens, Greece)

Published: March 19, 2025

Early Experience With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.

Early Experience With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: March 15, 2025

Sodium-Glucose Cotransporter 2 and Glucose Levels Affect Clear Cell Renal Cell Carcinoma Progression.

Sodium-Glucose Cotransporter 2 and Glucose Levels Affect Clear Cell Renal Cell Carcinoma Progression.

Journal: International journal of molecular sciences

Published: March 09, 2025

Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.

Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.

Journal: In vivo (Athens, Greece)

Published: February 15, 2025

Showing 1-12 of 60

Last Updated: 09/26/2026